Issue 32, 2026, Issue in Progress

Retraction: Molecular docking and in vivo/in vitro studies of a novel thiadiazole Schiff base as a hepatoprotective drug against angiogenesis induced by breast cancer

Abstract

Retraction of ‘Molecular docking and in vivo/in vitro studies of a novel thiadiazole Schiff base as a hepatoprotective drug against angiogenesis induced by breast cancer’ by Norah F. Alqahtani et al., RSC Adv., 2024, 14, 39027–39039, https://doi.org/10.1039/D4RA06398H.

Associated articles

Article information

Article type
Retraction
Submitted
20 May 2026
Accepted
20 May 2026
First published
28 May 2026
This article is Open Access
Creative Commons BY license

RSC Adv., 2026,16, 29153-29153

Retraction: Molecular docking and in vivo/in vitro studies of a novel thiadiazole Schiff base as a hepatoprotective drug against angiogenesis induced by breast cancer

N. F. Alqahtani, M. Y. Alfaifi, A. Shati A, S. E. I. Elbehairi, A. M. Saleh, E. S. Kotb, W. M. Serag, R. F. M. Elshaarawy, H. W. Alhamdi and Y. A. Hassan, RSC Adv., 2026, 16, 29153 DOI: 10.1039/D6RA90056A

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements